Shiliang Liu

机构：Sun Yat-sen University, Beijing Normal University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Henan Agricultural University · ORCID：0000-0001-5830-5171

发表论文 92 篇 · 总被引 1423 次 · h-index 23

代表论文

• Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial (2024 · Journal of Clinical Oncology · 被引 60)
• A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901) (2023 · EClinicalMedicine · 被引 51)
• Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab (2024 · Nature Communications · 被引 33)
• Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial (2024 · The Lancet Respiratory Medicine · 被引 32)
• Phase I study of cisplatin and nanoparticle albumin‐bound‐paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma (2023 · Cancer Medicine · 被引 17)
• Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis (2024 · International Journal of Radiation Oncology*Biology*Physics · 被引 12)